Abstract
No public abstract is available from the verified source records.
Leonardo Brunetti, Lisa Derosa
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
10.1016/s1470-2045(26)00191-9 · 2026
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
10.1056/nejmoa1709937 · 2017
Pretreatment risk model for radiation-induced lymphopenia is associated with adjuvant durvalumab efficacy in patients with unresectable stage III NSCLC
10.1016/j.ijrobp.2026.02.238 · 2026
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
10.1136/jitc-2020-001361 · 2020
No additional external references are available.